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ABSTRACT 
 
Rationale: There are several methods to measure cardiomyocyte (CM) and muscle contraction but these 
require customized hardware, expensive apparatus and advanced informatics or can only be used in single 
experimental models. Consequently, data and techniques have been difficult to reproduce across models 
and laboratories, analysis is time consuming and only specialist researchers can quantify data.  
 
Objective: Here we describe and validate an automated, open source software tool (MUSCLEMOTION) 
adaptable for use with standard laboratory- and clinical imaging equipment that enables quantitative 
analysis of normal cardiac contraction, disease phenotypes and pharmacological responses. 
 
Methods and Results: MUSCLEMOTION allowed rapid and easy measurement of movement from high-
speed movies in: (i) 1-dimensional in vitro models such as isolated adult and human pluripotent stem cell-
derived CMs (hPSC-CMs); (ii) 2-dimensional in vitro models, such as beating CM monolayers or small 
clusters of hPSC-CMs; (iii) 3-dimensional multicellular in vitro or in vivo contractile tissues such as cardiac 
"organoids", engineered heart tissues (EHT), zebrafish- and human hearts. MUSCLEMOTION was 
effective under different recording conditions (bright field microscopy with simultaneous patch clamp 
recording, phase contrast microscopy and traction force microscopy). Outcomes were virtually identical to 
the current gold standards for contraction measurement such as optical flow, pole deflection, edge-detection 
systems or manual analyses. Finally, we used the algorithm to quantify contraction in in vitro and in vivo 
arrhythmia models and to measure pharmacological responses. 
 
Conclusions: Using a single open source method for processing video recordings, we obtained reliable 
pharmacological data and measures of cardiac disease phenotype in experimental cell-, animal- and human 
models. 
 
Keywords:  
Pluripotent stem Cell-derived cardiomyocytes, contraction, basic science; arrhythmia, software tools. 
 
 
Nonstandard Abbreviations and Acronyms: 
 
AP action potential 
Cas9 CRISPR associated protein 9 
CM cardiomyocyte 
CRISPR clustered Regularly Interspaced Short Palindromic Repeats 
EHT Engineered Heart Tissue 
GNB5 guanine nucleotide binding protein, β subunit 5 
HCM hypertrophic cardiomyopathy  
hiPSC human induced pluripotent stem cell 
hiPSC-CM  human induced pluripotent stem cell-derived cardiomyocyte 
ISO isoprenaline 
LQT1 long-QT Syndrome Type 1 
MEA multi electrode array 
MHC myosin heavy chain 
MYH7 myosin heavy chain, isoform 7 
NIFE nifedipine 
PDMS polydimethylsiloxane 
SNR signal-to-noise ratio 
  
 by guest on January 10, 2018
http://circres.ahajournals.org/
D
ow
nloaded from
 
 DOI: 10.1161/CIRCRESAHA.117.312067    3 
INTRODUCTION 
 
The salient feature of cardiomyocytes (CMs) is their ability to undergo cyclic contraction and 
relaxation, a feature critical for cardiac function. In many research laboratories and clinical settings it is 
therefore essential that cardiac contraction can be quantified at multiple levels, from single cells to 
multicellular or intact cardiac tissues. Measurement of contractility is relevant for analysis of disease 
phenotypes, cardiac safety pharmacology, and longitudinal measures of cardiac function over time, both in 
vitro and in vivo. In addition, human genotype-phenotype correlations, investigation of cardiac disease 
mechanisms and the assessment of cardiotoxicity are increasingly performed on human induced pluripotent 
stem cells (hiPSCs) derived from patients1-3. Many of these studies are carried out in non-specialist 
laboratories so that it is important that analysis methods are simplified such that they can be used anywhere 
with access to just standard imaging equipment. Here, we describe a single method with high versatility 
that can be applied to most imaging outputs of cardiac contraction likely to be encountered in the laboratory 
or clinic. 
 
Electrical and calcium signals are usually quantified in vitro using established technologies such as 
patch clamp electrophysiology, multi electrode arrays (MEAs), cation-sensitive dyes or cation-sensitive 
genetic reporters4. Although experimental details differ among laboratories, the values for these parameters 
are with some approximations comparable across laboratories, cardiomyocyte source and cell culture 
configuration (e.g. single cells, multicellular 2-Dimensional (2D) CM monolayers, 3-Dimensional (3D) 
cultures)5,6. However, there is no comparable method for measuring cardiac contraction across multiple 
platforms, despite this being a crucial functional parameter affected by many diseases or drugs7. We have 
developed a method to address this that is built on existing algorithms and is fully automated, but most 
importantly can be used on videos, image stacks or image sequences loaded in the open source image 
processing program ImageJ8. Moreover, it is an open source, dynamic platform that can be expanded, 
improved and integrated for customized applications. The method, called MUSCLEMOTION, determines 
dynamic changes in pixel intensity between image frames and expresses the output as a relative measure of 
movement during muscle contraction and relaxation. We applied the concept to a range of biomedical- and 
pharmacologically relevant experimental models that included single hPSC-CMs, patterned- or 2D cultures 
of hPSC-CMs, cardiac organoids, engineered heart tissues (EHTs) and isolated adult rabbit CMs. Results 
were validated by comparing outputs of the tool with those from three established methods for measuring 
contraction: optical flow, post deflection and fractional shortening of sarcomere length. These methods 
have been tailored to (or only work on) specific cell configurations. Traction force microscopy, fractional 
shortening of sarcomere length and microposts are predominantly suitable for single cells8,9. Cardiomyocyte 
edge or perimeter detection is suitable for adult CMs but challenging for immature hPSC-CMs due to poorly 
defined plasma membrane borders and concentric contraction10, while large post deflection is suitable for 
EHTs or small cardiac bundles11 but less so for single cells. Our MUSCLEMOTION software by contrast 
can be used for all of these applications without significant adaptions. Furthermore, it can be used for multi-
parameter recording conditions and experimental settings using transmitted light microscopy, fluorescent 
membrane labeling, fluorescent beads embedded in soft substrates or patch clamp video recordings. Drug 
responses to positive and negative inotropic agents were evaluated across four different laboratories in 
multiple cell configurations using MUSCLEMOTION with reliable predictions of drug effects from all 
laboratories. Furthermore, MUSCLEMOTION was also applicable to optical recordings of zebrafish hearts 
in vivo, where it represented a significant time-saving in analysis, and in human echocardiograms. This 
versatile tool thus provides a rapid and straightforward way to detect disease phenotypes and 
pharmacological responses in vitro and in vivo. 
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METHODS 
 
Extended methods are in the Online Supplements.  
 
The datasets generated and/or analyzed during the current study are available from the corresponding 
authors on reasonable request. 
 
Code availability. 
MUSCLEMOTION source code has been written in the ImageJ Macro Language and is included in the 
Online Supplements and is available for use and further development.  
 
Model cell. 
The in silico cardiomyocyte-like model (Fig. 1d,f,g) was created using Blender v2.77.  
 
Optical flow analysis. 
Optical flow analysis was implemented in LabVIEW as described by Hayakawa et al.12,13. 
 
Generation of hiPSC-HCM isogenic triplet using CRISPR/Cas9. 
Dual guide RNA/Cas9-Nickase strategy was designed to introduce the MYH7-C9123T SNP (encoding the 
R453C-β-MHC modification) in ReBL-PAT hiPSC line, as previously described14. 
 
hPSC culture and differentiation. 
hPSCs from multiple independent cell lines (Online Table I) were differentiated to CMs as previously 
described15-18, or with the Pluricyte® Cardiomyocyte Differentiation Kit (Pluriomics b.v.) according to the 
manufacturer’s protocol. Experiments were performed at 18-30 days after initiation of differentiation, 
depending on the cell source and configuration. Pluricytes® were kindly provided by Pluriomics b.v. 
 
Patch clamp recordings on hPSC-CMs. 
Electrophysiological recordings of isolated hPSC-CMs were performed as previously described17.  
 
MEA recordings of hPSC-CMs. 
Field potentials from MEAs were recorded and analyzed as previously published19. 
 
Movement of embedded beads. 
Gelatin-patterned polyacrylamide gels containing fluorescent beads were generated and analyzed as 
described previously20. 
 
Monolayers of hPSC-CMs. 
25k-40k cells were plated per Matrigel-coated glass ø10 mm coverslip. 
  
Cardiac organoids. 
Cardiac organoids composed of hPSC-CMs and hPSC-derived endothelial cells, were generated as 
previously described18.  
 
Adult cardiomyocytes. 
CMs were isolated from New Zealand White male rabbits as previously described21.  
 
Membrane labelling. 
hPSC-CMs were plated on Matrigel-coated glass-bottom 24-well plates and labelled with CellMask Deep 
Red according to the manufacturer’s instructions. 
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Engineered heart tissues. 
EHTs were generated and analyzed as previously described15.  
 
Zebrafish hearts. 
Zebrafish hearts were recorded, treated and analysed as previously described22. 
 
Echocardiograms. 
Anonymized ultrasounds of 5 adult patients were selected from the echocardiography database of the 
Leiden University Medical Center.  
 
Statistics. 
One-way ANOVA for paired or unpaired measurements was applied to test the differences in means on 
normalized drug effects. P-values obtained from two-tailed pairwise comparisons were corrected for 
multiple testing using Bonferroni’s method. Statistical analyses were performed with R v3.3.3. P-values 
lower than 0.05 were considered statistically significant and indicated with an asterisk (*). N-values 
represent biological repeats. 
 
 
 
RESULTS 
 
Algorithm development. 
 
The principle underlying the algorithm of MUSCLEMOTION is the assessment of contraction 
using an intuitive approach quantifying absolute changes in pixel intensity between a reference frame and 
the frame of interest, which can be described as  
 
ห݅݉݃௜ െ 	݅݉݃௥௘௙ห ൌ 	 ݅݉݃௥௘௦௨௟௧ 
 
where ݅݉݃௜ is the frame of interest, ݅݉݃௥௘௙ is the reference frame and ݅݉݃௥௘௦௨௟௧ is the resulting image. For 
every pixel in the frame, each reference pixel is subtracted from the corresponding pixel of interest and the 
difference is presented in absolute numbers. Unchanged pixels result in low (black) values, while pixels 
that are highly changed result in high (white) values (Fig. 1a). Next, the mean pixel intensity of the resulting 
image is measured. This is a quantitative measure of how much the pixels have moved compared to the 
reference frame: more white pixels indicate more changing pixels and, thus, more displacement. When a 
series of images is analysed relative to the same reference image, the output describes the accumulated 
displacement over time (measure of displacement, Fig. 1b). 
 
However, if a series of images is analysed with a reference frame that depends on the frame of 
interest (e.g. ݅݉݃௥௘௙ ൌ ݅݉݃௜ିଵ), this results in a measure of the relative displacement per interframe 
interval. We defined this parameter as contraction velocity (measure of velocity, Fig. 1b). 
 
Since velocity is the first derivative of displacement in time, the first derivative of the measure of 
displacement should resemble the measure of velocity derived from image calculations. To test the linearity 
of the method, three movies of moving blocks were analysed. The block moved back and forth at two 
different speeds in each direction (where ݒଶ ൌ 2 ∙ ݒଵ): i) along the x-axis, ii) along the y-axis and iii) along 
both axes (Online Movie I). As expected, the measure of displacement and velocity showed a linear 
correlation (Online Figure I). This does not hold when the position of the block in ݅݉݃௜ does not overlap 
the position of the block in ݅݉݃௥௘௙, with a consequent saturation in the measure of displacement (i.e. max 
 by guest on January 10, 2018
http://circres.ahajournals.org/
D
ow
nloaded from
 
 DOI: 10.1161/CIRCRESAHA.117.312067    6 
pixel white value, Online Figure II). Therefore, comparison of the differentially derived velocities should 
approximately overlap in the absence of pixel saturation. This was used as a qualitative parameter to 
determine whether the algorithm outputs were reliable.  
 
Algorithm implementation. 
 
MUSCLEMOTION was then modified to handle typical experimental recordings by (i) improving 
the signal-to-noise ratio (SNR), (ii) automating reference frame selection and (iii) programming built-in 
checks to validate the generated output data (Fig. 1c). The SNR was increased by isolating the pixels of 
interest in a three-step process: i) maximum projection of pixel intensity in the complete contraction stack, 
ii) creation of a binary image of this maximum projection with a threshold level equal to the mean grey 
value plus standard deviation and iii) multiplication of the pixel values in this image by the original 
contraction and speed of the contraction image stack (Online Figure III). This process allowed the algorithm 
to work on a region of interest with movement above the noise level only. 
 
Next, a method was developed to identify the correct ݅݉݃௥௘௙ from the speed of contraction image 
stack by comparing values obtained from the frame-to-frame calculation with their direct neighbouring 
values, while also checking for the lowest absolute value (Online Figure IV).  
 
The reliability of MUSCLEMOTION for structures with complex movements was validated using 
a custom-made contracting 3D “synthetic CM” model (Fig. 1d,f,g) that was adapted to produce contractions 
with known amplitude and duration. Linearity was preserved during the analysis of the contraction and 
velocity; other output parameters of the analysis matched the input parameters (Fig. 1e). A second 3D model 
(Fig. 1g), with a repetitive pattern aimed to create out-of-bounds problems was also generated. As expected, 
contraction amplitude information here was not linear (Fig. 1e), although contraction velocity and temporal 
parameters did remain linear (Fig. 1e,g). To mitigate this problem, we implemented an option for a 10-
sigma Gaussian blur filter that can be applied on demand to biological samples that presented highly 
repetitive patterns (e.g. sarcomeres in adult CMs).  
 
Algorithm application to multiple cell configurations and correlation with existing gold standards. 
 
This set of experiments aimed to investigate the versatility of MUSCLEMOTION and examine 
how its performance compared with standard measures used in each system: i) optical flow for isolated 
hPSC-CMs, monolayers and organoids; ii) post deflection for EHT; iii) sarcomere length fractional 
shortening for adult CMs. Remarkably, standard methods currently used measure only contraction or 
contraction velocity. Linearity was preserved in all cases during the analyses, demonstrating the reliability 
of the results (Online Figure V).  
 
First, single hPSC-CMs (Fig. 2a, Online Movie II) exhibited concentric contraction (Fig. 2a ii) and 
contraction velocity amplitudes correlated well with the amplitudes obtained by optical flow analysis (R2 = 
0.916) (Fig. 2a v). In contrast to single cells, the area of contraction for hPSC-CM monolayers was 
distributed heterogeneously throughout the whole field (Fig. 2b ii, Online Movie III). Optical flow analysis 
was compared with our measure of velocity (Fig. 2b iv); this showed a good linear correlation (R2 = 0.803) 
(Fig. 2b v). Complex (mixed, multicellular) 3D configurations were also investigated by analyzing hPSC-
derived cardiac organoids18 (Online Movie IV) and EHTs15 (Online Movie V). Cardiac organoids showed 
moderate levels of contraction throughout the tissue (Fig. 2c ii), while the EHTs showed high deflection 
throughout the bundle (Fig. 2d ii). The contraction velocity of the organoids correlated well with the output 
of optical flow analysis (R2 = 0.747, Fig. 2c v). Similarly, contraction amplitudes in EHTs showed high 
linear correlation (R2 = 0.879) with the absolute force values derived from measurement of pole deflection 
(Fig. 2d v). Finally, single adult rabbit ventricular CMs were analyzed (Fig. 2e, Online Movie VI). Large 
movement was evident around the long edges of the CM (Fig. 2e ii). These cells were analyzed with a 10-
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sigma Gaussian blur filter, which also minimized (unwanted) effects of transverse movements on 
contraction patterns. Linearity was preserved (Online Figure V) despite the repetitive pattern of the 
sarcomeres and this resulted in accurate measures of both contraction (Fig. 2e iii) and speed of contraction 
(Fig. 2e iv). The contraction amplitude of the adult CMs stimulated at 1 Hz correlated well with the output 
of sarcomeric shortening using fast Fourier transform analysis23 (R2 = 0.871, Fig. 2e v). Thus, the 
MUSCLEMOTION algorithm yielded data in these initial studies comparable with methods of analysis 
tailored for the individual platforms. 
 
Application of MUSCLEMOTION to multiple imaging and recording platforms. 
 
To examine whether MUSCLEMOTION could potentially be used in applications that measure 
other aspects of CMs functionality in parallel, we first determined the electrophysiological properties of 
hPSC-CMs using patch clamp whilst recording their contractile properties through video imaging. This 
allowed simultaneous quantitative measurement of action potentials (APs) and contraction (Fig. 3a), for in-
depth investigation of their interdependence. We observed a typical24 profile of AP followed by its delayed 
contraction.  
 
To measure contractile force in combination with contractile velocity in single CMs, we integrated 
fluorescent beads into polyacrylamide substrates patterned with gelatin (Fig. 3b), where the displacement 
of the beads is a measure of CM contractile force20 (Online Movie VII). Additionally, field potentials and 
contraction profiles of hPSC-CMs were analyzed from simultaneous electrical and video recordings of 
monolayers plated on MEAs (Fig 3c, Online Movie VIII). 
 
Similarly, effective quantification of contraction profiles was obtained for fluorescently labeled 
hPSC-CM monolayer cultures (Fig. 3d, Online Movie IX), allowing MUSCLEMOTION to be integrated 
on high speed fluorescent microscope systems for automated data analysis. 
 
Application of MUSCLEMOTION to drug responses in different cell models in different laboratories. 
 
Having shown that MUSCLEMOTION was fit-for-purpose in analyzing contraction over a variety 
of platforms, we next sought to demonstrate its ability to detect the effects of positive and negative 
inotropes. This is essential for ensuring the scalability of the tool over multiple platforms, particularly in 
the context of hiPSC-CMs where regulatory authorities and pharmaceutical companies are interested in 
using these cells as human heart models for drug discovery, target validation or safety pharmacology25. For 
isoprenaline (ISO) and nifedipine (NIFE) the main parameters of interest are: contraction amplitude (ISO, 
NIFE), relaxation time (ISO) and contraction duration (NIFE). 
 
The relaxation time of spontaneously beating isolated hPSC-CMs on gelatin patterned 
polyacrylamide substrates treated with ISO significantly decreased as expected at doses higher than 1 nM. 
Similar to what has been reported27, contraction amplitude decreased at doses higher than 1 nM. NIFE 
treatment decreased both contraction amplitude and duration starting from 3 nM, respectively (Fig. 4a). In 
paced (1.5 Hz) hPSC-CMs monolayers, no significant effects were measured after addition of ISO on either 
relaxation time or contraction amplitude. NIFE caused a progressive decrease in contraction duration and 
amplitude in a concentration-dependent manner starting at 100 nM (Fig. 4b). Similarly, cardiac organoids 
paced at 1.5 Hz showed no significant effects on both relaxation time and contraction amplitude with ISO, 
while both parameters decreased after NIFE, starting from 100 nM and 300 nM, respectively (Fig. 4c). 
EHTs paced at 1.5 times baseline frequency and analyzed with MUSCLEMOTION showed a positive 
inotropic effect starting from 1 nM ISO and a negative inotropic effect starting at 30 nM NIFE as previously 
reported15 (Fig. 4d). 
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Paced (1 Hz) adult rabbit CMs exhibited no significant increase in relaxation time and contraction 
amplitude at any ISO concentration. At concentrations higher than 3 nM, adult CMs exhibited after-
contractions and triggered activity during diastole, which hampered their ability to be paced at a fixed 
frequency. No significant effects were observed on contraction duration with NIFE, while contraction 
amplitude significantly decreased in a dose-dependent manner starting from 100 nM (Fig. 4e). Data 
generated by post deflection and sarcomere fractional shortening are available for comparison purposes in 
Online Figure VI. 
 
Analysis of disease phenotypes in vitro. 
 
Contractility of hiPSC-CMs carrying mutations associated with Long QT Syndrome Type 1 
(LQT1)26 and hypertrophic cardiomyopathy (HCM) were characterized in distinct cell configurations: 
monolayers plated on MEAs and EHTs, respectively. As demonstrated previously, LQT1 phenotype was 
captured as a prolongation of the QT interval of the field potential17,26. As expected, contraction duration 
measured with MUSCLEMOTION was also prolonged (Fig. 5a,b). EHTs were fabricated from an isogenic 
triplet carrying the MYH7R453C mutation either in homozygosity or heterozygosity and showed a gene 
dosage effect on the contractility recapitulating disease severity.  
 
Analysis of disease phenotypes in vivo. 
 
To extend analysis to hearts in vivo, we took advantage of the transparency of zebrafish, which 
allows recording of contracting cardiac tissue in vivo (Fig. 6a, Online Movie X). It was previously shown 
that mutations in G protein β subunit 5 (GNB5) are associated with a multisystem syndrome in human, with 
severe bradycardia at rest. Zebrafish with loss of function mutations in gnb5a and gnb5b were generated. 
Consistent with the syndrome manifestation in patients, zebrafish gnb5a/gnb5b double mutant embryos 
showed severe bradycardia in response to parasympathetic activation22. Irregularities in heart rate were 
visually evident and were clearly distinguishable from the wild type counterpart after analysis with 
MUSCLEMOTION (Fig. 6b). Quantification of the heart rate of these zebrafishes with MUSCLEMOTION 
highly correlated (R2 = 0.98) with the results of the published manual analyses22 (Fig. 6c). There was 
however, a striking time-saving for operators in carrying out the analysis using the algorithm (5-10 times 
faster than manual analysis; 150 recordings were analysed in 5 hours versus 4 days) without compromising 
accuracy of the outcome. Qualitative analysis of contraction patterns allowed rapid discrimination between 
arrhythmic vs non-arrhythmic responses to carbachol treatment (Fig. 6c). 
 
Finally, we examined human echocardiograms from five healthy and cardiomyopathic individuals 
(Fig. 6d, Online Movie XI). To assess ventricular function, videos were cropped to exclude movement 
contributions of the atria and valves. MUSCLEMOTION enabled rapid quantification of temporal 
parameters from standard ultrasound echography (Fig. 6e) such as time-to-peak, relaxation time, RR 
interval and the contraction duration (Fig. 6f).  
 
 
 
DISCUSSION 
 
A reliable and easy-to-use method to quantify cardiac muscle contraction would be of significant 
benefit to many basic and clinical science laboratories to characterize cardiac disease phenotypes, 
understand underlying disease mechanisms and predicting cardiotoxic effects of drugs15,27. Quantification 
of frame-to-frame differences in pixel intensity has been used in recent reports with success10; however, the 
full spectrum of applications for which these algorithms are relevant, how their output data correlates with 
gold standards in each system and software performance, specifications, license and software availability, 
have remained unclear.  
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Here we developed and tested a user-friendly, inexpensive, open source software platform that 
serves this purpose in a variety of biological systems of heart tissue. Its integration into current research 
practices would benefit data sharing, reproducibility, comparison and translation in many clinically relevant 
contexts28. 
 
The linearity and reliability of MUSCLEMOTION were validated using a 3D reconstructed 
artificial CM which gave the expected linear correlations between known inputs and the outputs (Fig. 1d-
f). When random repetitive patterns were applied, amplitude outputs differed from inputs, suggesting a 
potential limitation to measuring contraction amplitudes in highly repetitive biological samples (such as 
when sarcomere patterns are well-organized), while temporal parameters remained valid (Fig. 1d,e,g). 
However, conditions such as these would be unlikely in standard biological samples, where camera noise 
significantly reduces the possibility of saturating pixel movement. We partially attenuated this problem by 
applying, on user demand, a 10-sigma Gaussian blur filter which significantly increased the accuracy of 
MUSCLEMOTION with highly repetitive structures. Also, to increase reliability, we built in additional 
controls to detect any mismatches and errors. MUSCLEMOTION can automatically identify and select the 
reference frame and increase the signal-to-noise-ratio, features which were particularly relevant in reducing 
user bias and interaction while improving user experience. MUSCLEMOTION is valid in a wide range of 
illumination conditions without changing temporal parameters; however, exposure time was linearly 
correlated with contraction amplitude (Online Figure VII). Furthermore, a series of conditions in which 
there is no contraction has been used as a negative control (Online Figure VIII). Batch mode analyses and 
data storage in custom folders were also incorporated to support overnight automated analyses. For accurate 
quantification of amplitude, time-to-peak and relaxation time, an appropriate sampling rate should be 
chosen. For applications similar to those described here, we recommend recording rates higher than 70 
frames per second to sample correctly the fast upstroke of the time-to-peak typical of cardiac tissue. This 
recording rate is easily achievable even using smartphone slow motion video options (~120/240 frames per 
second), obviating the need for dedicated cameras and recording equipment if necessary.  
 
We demonstrated excellent linear correlations between our software tool and multiple other 
standard methods independent of substrate, cell configuration and technology platform and showed that 
MUSCLEMOTION is able to capture contraction in a wide range of in vivo and in vitro applications (Fig. 
2 and Fig. 3). Specifically, we identified several advantages compared to optical flow algorithms in terms 
of speed and the absence of arbitrary binning factors or thresholds which, when modified, profoundly affect 
the results. One limitation compared to optical flow or EHT standard algorithm is that the tool lacks 
qualitative vector orientation, making it more difficult to assess contraction direction. Particularly important 
was the correlation with force data calculated from the displacement of flexible posts by EHTs. This 
indicates that when the mechanical properties of substrates are known29, MUSCLEMOTION allows 
absolute quantification of contractile force. Technical limitations of the EHT recording system allowed us 
to analyze only movies with JPEG compression; this resulted in loss of pixel information that might have 
negatively influenced the correlation shown. For better and more accurate results on contraction 
quantification, non-lossy/uncompressed video formats should be used for recordings since individual pixel 
information is lost upon compression and therefore not available for analysis by MUSCLEMOTION. 
 
We proposed and validated practical application in pharmacological challenges using multiple 
biological preparations recorded in different laboratories; this means that immediate use in multiple 
independent high-throughput drug-screening pipelines is possible without further software development 
being required, as recently applied for a drug screening protocol on cardiac organoids from hPSCs18. 
Intuitively, the possibility of having inter-assay comparisons will also be of particular relevance where 
comparisons of contraction data across multiple platforms are required by regulatory agencies or consortia 
(e.g. CiPA, CSAHi)5,6,25,30. Moreover, this might offer a quantitative approach to investigating how genetic 
or acquired diseases of the heart (e.g. cardiomyopathies7, Long QT Syndrome31), heart failure resulting 
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from anticancer treatments32,33 or maturation strategies20,34,35 affect cardiac contraction. The possibility of 
linking in vitro with in vivo assays, with low cost technologies applicable with existing hardware certainly 
represents an advantage as demonstrated by automatic quantification of zebrafish heartbeats and human 
echocardiograms (Fig. 6). Overall, these results clearly demonstrated that contraction profiles could be 
derived and quantified in a wide variety of commonly used experimental and clinical settings. 
MUSCLEMOTION might represent a starting point for a swift screening method to provide clinically 
relevant insights into regions of limited contractility in the hearts of patients. We encourage further 
development of this open source platform to fit specific needs; future areas of application could include 
skeletal or smooth muscle in the same range of formats described here.  
 
MUSCLEMOTION allows the use of a single, transparent method of analysis of cardiac contraction 
in many modalities for rapid and reliable identification of disease phenotypes, potential cardiotoxic effects 
in drug screening pipelines and translational comparison of contractile behaviour.   
 
Limitations. 
 
Saturation of pixel movements may affect contraction amplitudes. However, as demonstrated with 
the artificial CM, contraction velocity and all temporal parameters remained valid. We also minimized the 
impact of highly repetitive structures on the output of MUSCLEMOTION by applying a Gaussian filter, 
which also helped in reducing the impact of transverse movements on contraction profiles. High frequency 
contraction might complicate baseline detection, especially if the duration of the contracted state is similar 
to that of the relaxed (e.g. approaching sinusoidal). We have implemented a “fast mode” option that captures 
reliable baseline values even at high contraction rates. MUSCLEMOTION does not measure absolute 
values of cell shortening or force of contraction. However, as demonstrated by correlations with these 
physical quantities (Fig. 2d,e v), specific setups can be calibrated to obtain such readout.  
 
Adult CMs contract dominantly along the longitudinal axis. However, hPSC-CMs are highly 
variable in shape, often showing concentric contractions, so that effects of transverse movement are usually 
intrinsic to the experimental model and they should be considered in the global contraction analysis. Indirect 
transverse movements originating from uncontrolled experimental conditions or moving objects other than 
those of interest (e.g. vibrations, sample shift, floating debris, air bubbles, etc.) should be avoided since 
they might lead to overestimation of the cardiomyocyte contraction. 
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FIGURE LEGENDS 
Figure 1: Algorithm construction and validation. a) Principle of pixel intensity difference by subtraction 
of imgref of imgi and measurement of the non-zero area after image subtraction.  b) Principle of using pixel 
intensity difference as a measure of displacement and as a measure of displacement velocity.  c) Schematic 
overview of MUSCLEMOTION. Green blocks indicate basic steps of the algorithm. Dark green blocks 
indicate important user input choices. Plots within light green blocks indicate results. Optional steps are 
shown in blue blocks, with graphical representation of the analysed parameters indicated by red lines. Three 
result files are generated containing the raw data: “contraction.txt”, “speed-of-contraction.txt” and 
“overview-results.txt”. Furthermore, three images showing relevant traces and a log file are generated and 
saved (not shown in schematic).  d) Schematic of the contractile pattern of the artificial cell and relative 
parameters corresponding to amplitude of contraction (A), time-to-peak (t1) and relaxation time (t2). 
e) Correlation between input (x axis) and output (y axis) parameters used to validate MUSCLEMOTION 
with two artificial cells. f-g) Frame representing the two artificial cells built for MUSCLEMOTION 
validation and their relative output parameters. 
 
Figure 2: Correlation of results with gold standards.  a) Brightfield image of isolated hPSC-CMs (i), 
with maximum projection step visually enhanced with a fire Look Up Table (ii), contraction (iii) and 
velocity (iv) profiles of each individual beat have been generated by MUSCLEMOTION and temporally 
aligned; linear regression analysis between MUSCLEMOTION results (x-axis) and optical flow results (y-
axis) (v). b) Phase contrast image of hPSC-CM monolayers (i), with maximum projection step visually 
enhanced with a fire Look Up Table (ii), contraction (iii) and velocity (iv) profiles of each individual beat 
have been generated by MUSCLEMOTION and temporally aligned; linear regression analysis between 
MUSCLEMOTION results (x-axis) and those obtained with optical flow results (y-axis) (v). c) Phase 
contrast image of cardiac organoids (i), with maximum projection step visually enhanced with a fire Look 
Up Table (ii), contraction (iii) and velocity (iv) profiles of each individual beat have been generated by 
MUSCLEMOTION and temporally aligned; linear regression analysis between MUSCLEMOTION results 
(x-axis) and those obtained with optical flow results (y-axis) (v). d) Live view of an EHT during contraction 
analysis. Scale bar = 1 mm. (i), with maximum projection step visually enhanced with a fire Look Up Table 
(ii), contraction (iii) and velocity (iv) profiles of each individual beat have been generated by 
MUSCLEMOTION and temporally aligned; linear regression analysis between MUSCLEMOTION results 
(x-axis) and those obtained with post deflection (y-axis) (v). e) Brightfield image of adult rabbit CMs (i), 
with maximum projection step visually enhanced with a fire Look Up Table (ii); contraction (iii) and 
velocity (iv) profiles of each individual beat have been generated by MUSCLEMOTION and temporally 
aligned; linear regression analysis between MUSCLEMOTION results (x-axis) and those obtained from 
sarcomere fractional shortening calculation with Fast Fourier Transform (y-axis) (v).  For details on cell 
sources and cell lines please refer to the Online Table I. 
 
Figure 3: Application of contraction tool to multiple biological situations. Representative examples 
with enhancement of moving pixels (top) and profiles (bottom) of contraction (a-d, red), velocity (a-d, 
black) and voltage (a, c, blue) respectively obtained from high speed movies of patched hPSC-CMs (a), 
aligned hPSC-CMs on polyacrylamide gels with fluorescent beads (b), monolayers of hiPSC-CMs seeded 
on MEAs (c) and hPSC-CMs whose membranes have been labelled with CellMask Deep Red (d). For 
details on cell sources and cell lines please refer to the Online Table I. 
 
Figure 4: Pharmacological challenge with positive and negative inotropic compounds. a) Average 
dose-response curves (black traces) and single measurements for several parameters obtained in isolated, 
spontaneously beating, aligned hPSC-CMs treated with isoprenaline (left, red) and nifedipine (right, 
green).  b) Average dose-response curves (black traces) and single measurements for several parameters 
obtained from monolayers of hPSC-CMs treated with isoprenaline (left, red) and nifedipine (right, green).  
 by guest on January 10, 2018
http://circres.ahajournals.org/
D
ow
nloaded from
 
 DOI: 10.1161/CIRCRESAHA.117.312067    15 
c) Average dose-response curves (black traces) and single measurements for several parameters obtained 
in cardiac organoids treated with isoprenaline (left, red) and nifedipine (right, green). d) Average dose-
response curves (black traces) and single measurements for several parameters obtained in EHTs treated 
with isoprenaline (left, red) and nifedipine (right, green). e) Average dose-response curves (black traces) 
and single measurements for several parameters obtained in adult rabbit CMs treated with isoprenaline (left, 
red) and verapamil (right, green).  Average data points (black) represent mean ± standard error of mean. 
For details on cell sources and cell lines please refer to the Online Table I.  Data information: P-values 
DMSO versus dose. Panel a i) 0.3 nM: 0.2897; 1 nM: 3.4·10-6; 3 nM: 3.8·10-8; 10 nM: 7·10-11; 30 nM: 
7.3·10-10; 100 nM: 2.4·10-10. Panel a ii) 0.3 nM: 1; 1 nM: 0.0645; 3 nM: 0.0136; 10 nM: 8.2·10-5; 30 nM: 
0.0063; 100 nM: 2.4·10-6. (N=14; 14; 14; 14; 14; 14; 14) Panel a iii) 3 nM: 0.6533; 10 nM: 4·10-5; 30 nM: 
2·10-9; 100 nM: 1.5·10-15. Panel a iv) 3 nM: 0.00054; 10 nM: 1.9·10-11; 30 nM: < 2·10-16; 100 nM: < 2·10-
16. (N=14; 14; 14; 14; 14) P-values baseline versus dose. Panel b i) 1 nM: 1; 3 nM: 1; 10 nM: 1; 30 nM: 1; 
100 nM: 1; 300 nM: 1. Panel b ii) 1 nM: 1; 3 nM: 1; 10 nM: 1; 30 nM: 1; 100 nM: 1; 300 nM: 1. (N=6; 
5; 6; 6; 6; 6; 6) Panel b iii) 3 nM: 1; 10 nM: 1; 30 nM: 1; 100 nM: 0.00801; 300 nM: 2.7·10-9; 1000 nM: 
1.8·10-10. Panel b iv) 3 nM: 1; 10 nM: 1; 30 nM: 1; 100 nM: 0.00084; 300 nM: 2.9·10-11; 1000 nM: 1.5·10-
11. (N=6; 6; 6; 6; 6; 6; 6) P-values baseline versus dose. Panel c i) 1 nM: 1; 3 nM: 1; 10 nM: 1; 30 nM: 1; 
100 nM: 1; 300 nM: 1. Panel c ii) 1 nM: 1; 3 nM: 1; 10 nM: 1; 30 nM: 1; 100 nM: 1; 300 nM: 1. (N=5; 
5; 4; 5; 4; 4; 4) Panel c iii) 3 nM: 1; 10 nM: 1; 30 nM: 1; 100 nM: 0.00181; 300 nM: 2.9·10-6; 1000 nM: 
1.7·10-5. Panel c iv) 3 nM: 1; 10 nM: 1; 30 nM: 1; 100 nM: 0.54836; 300 nM: 0.01392; 1000 nM: 8.2·10-
5. (N=5; 5; 4; 5; 5; 5; 3) P-values baseline versus dose. Panel d i) 1 nM: 1; 3 nM: 1; 10 nM: 1; 30 nM: 
0.47; 100 nM: 1. Panel d ii) 1 nM: 0.02318; 3 nM: 0.00170; 10 nM: 0.00028; 30 nM: 0.00044; 100 nM: 
0.00113. (N=5; 5; 5; 5; 5; 5). Panel d iii) 3 nM: 1; 10 nM: 1; 30 nM: 1; 100 nM: 3·10-5. Panel d iv) 3 nM: 
1; 10 nM: 0.49856; 30 nM: 0.01473; 100 nM: 7·10-6. (N=6; 6; 6; 6; 6) P-values Krebs versus dose. Panel 
e i) 1 nM: 1; 3 nM: 1. Panel e ii) 1 nM: 1; 3 nM: 0.54. (N=6; 10; 7)  P-values DMSO versus dose. Panel e 
iii) 10 nM: 1; 30 nM: 1; 100 nM: 1; 300 nM: 1. Panel e iv) 10 nM: 0.5298; 30 nM: 0.2470; 100 nM: 
0.0054; 300 nM: 0.0029. (N=7; 8; 4; 5; 7). 
 
Figure 5: In vitro disease phenotypes. a) Field potential and contraction profile of wildtype (black) and 
LQT1 (gray) hPSC-CM monolayers on MEAs. b) Quantitative analysis of the QT interval and the 
contraction duration.  c) Raw (top) and normalized (bottom) contraction profiles of HCM-EHTs from 
MYH7wt/wt (solid), MYH7wt/mut (dashed), MYH7mut/mut (dotted) cell lines. d) Quantitative analysis of 
contraction amplitude and contraction duration. Data information: P-values QT-interval: WT versus 
LQT1: 0.012. P-values contraction duration: WT versus LQT1: 0.012.  P-values contraction amplitude: 
MYH7wt/wt versus MYH7wt/mut: 0.026; MYH7wt/wt versus MYH7mut/mut: 6·10-6; MYH7wt/mut versus 
MYH7mut/mut: 0.00065. P-values contraction duration: MYH7wt/wt versus MYH7wt/mut: 0.062; MYH7wt/wt 
versus MYH7mut/mut: 0.00085; MYH7wt/mut versus MYH7mut/mut: 0.0046. 
 
Figure 6: In vivo disease phenotypes. a) Representative examples of wild type (top) and gnb5a/gnb5b 
mutant (bottom) zebrafishes and relative enhancement of moving pixels.   b) Representative qualitative 
analyses of normal (top) and arrhythmic (bottom) contraction profiles from wild type and gnb5a/gnb5b 
mutant zebrafishes treated with carbachol. c) Correlation of results obtained from manual (x-axis) vs 
automatic (y-axis) detection of beating frequency (top); distribution of normal (green) and arrhythmic (red) 
contraction patterns in baseline condition (B) and after treatment with carbachol (C) in wild type and 
gnb5a/gnb5b mutant zebrafishes (bottom). d) Representative echocardiograms of healthy (top) and 
cardiomyopathic (bottom) human individuals. Ventricles have been manually cropped and the 
enhancement of moving pixels is overlaid. e) Representative qualitative analyses of normal (top) and poor 
(bottom) ventricular functions.  f) Quantitative data collected from echocardiogram in 5 individuals. Each 
colour represents one individual. 
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NOVELTY AND SIGNIFICANCE 
 
What Is Known? 
 
 Quantification of cardiac contraction in vitro and in vivo is essential to characterise effects of drugs 
and disease on cardiac myocyte and heart function. 
 
 Most current software tools to measure and quantify contraction require tailored hardware, 
expensive software licences, arbitrary analysis thresholds or advanced informatics skills not 
available in many laboratories. 
 
 Validation of data and reproducibility across different laboratories, platforms or cell configurations 
is   limited because complex data analysis methodologies are not directly comparable. 
 
What New Information Does This Article Contribute? 
 
 MUSCLEMOTION is an open source, simple, software tool created and validated with current 
gold standards for measurement across different laboratories to analyse contraction of cardiac 
myocytes and hearts from high-speed movies.  
 
 MUSCLEMOTION can measure and quantify contraction from multiple recording conditions, cell 
configurations and genotypes in vitro and in vivo. Absolute force values or displacement values 
can be obtained upon calibration.  
 
 MUSCLEMOTION code is freely available and can be easily implemented by scientists and 
clinicians in basic and applied research. 
 
Contractile function of the heart is often impaired in cardiac disease and in response to drugs, where there 
may be alterations in the force, duration and amplitude of contraction. In this study, cardiac research 
scientists and clinicians pooled expertise to create and validate a new software tool, called 
MUSCLEMOTION, which serves as a flexible platform for quantification of cardiac contraction in many 
commonly used recording conditions or cell configurations; importantly, MUSCLEMOTION is open 
source and shared here to promote data reproducibility, data comparison and offer others in the field a 
reliable and robust starting point to which tailored applications may be developed.  MUSCLEMOTION can 
be used effectively to validate the functional consequences of disease on cell contraction, to quantify and 
compare relative or absolute parameters in different culture conditions, drug responses or even to 
characterise in vivo disease models and patient cardiac echography profiles. 
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SUPPLEMENTAL MATERIAL 
 
Versatile open software to quantify cardiomyocyte and cardiac muscle contraction in 
vitro and in vivo 
Sala L.#, van Meer B.J.# et al.  
 
Supplementary Methods 
Model Cell  
To establish and test the algorithm of MUSCLEMOTION we first created an in silico CM-like shape 
(Fig. 1d,f,g) using Blender v2.77 (Stichting Blender Foundation). This three-dimensional squared 
sphere had an aspect ratio of 1:1:0.26 (XYZ) when contracted and 2:1:0.26 (XYZ) when relaxed. A 
diffuse “shader” with a foggy, patterned texture was then applied to the object to simulate extremely 
repetitive phase contrast image features. Temporal input parameters were then imposed: 100 ms for 
time-to-peak (t1) and 350 ms for relaxation time (t2). A beating frequency of 1 Hz and sampling rate 
of 100 frames per second were simulated. Modifications of cell shortening (25% and 50% of baseline) 
and time-to-peak (50% and 200% of baseline) were generated to validate the algorithm linearity.  
 
Patch Clamp Recordings on hPSC-CMs 
Electrophysiological recordings of isolated hPSC-CMs were performed using the perforated patch 
clamp technique as previously described1. Briefly, cells were paced at 1 Hz through the glass capillary 
and were perfused with warm (37 °C) Tyrode’s solution containing (mM): 154 NaCl, 5.4 KCl, 1.8 
CaCl2, 1 MgCl2, 5 HEPES-NaOH, 5.5 D-Glucose; pH was adjusted to 7.35 with NaOH. 
Pipette solution contained (mM): 125 K-Gluconate, 20 KCl, 10 NaCl, 10 HEPES; pH was adjusted to 
7.2 with KOH. Amphotericin-B was dissolved in DMSO right before each experiment and added to 
the pipette solution to reach a final concentration of 0.22 mM. 
 
Movement of embedded beads  
Fabrication of gelatin-patterned polyacrylamide gels containing fluorescent beads and contraction 
force measurements were performed as described previously2, with an increased recording frame rate 
to 56 frames per second. For nifedipine experiments, cells were paced through an external stimulator 
to ensure a constant and triggered beating rate. Experiments with isoprenaline were performed in 
spontaneously beating aligned hPSC-CMs to investigated the pharmacological effect on beat rate. 
hPSC-CMs on patterned polyacrylamide gels were measured in Pluricyte® medium (Pluriomics b.v.). 
Drug treatment was performed with additive doses which were compared to baseline.	
 
Monolayers of hPSC-CMs 
Pluricytes® (Pluriomics b.v.) were cultured following the manufacturer’s instructions. Cells were 
plated at a density of 25k-40k cells/coverslip on Matrigel-coated glass ø10 mm coverslips for 7 days 
before measurements of contraction. Monolayers were paced by an external field stimulator (bipolar 
square pulse of ~15V for 5 ms) and superfused with a warm (37 °C) Tyrode’s solution (described 
above). Drug treatment was performed with additive doses which were compared to baseline. 
 
Cardiac Organoids 
Cardiac organoids composed of hPSC-CMs and hPSC-derived endothelial cells were generated as 
previously described3. Cardiac organoids were paced through an external field stimulator (bipolar 
square pulse of ~15V for 5 ms) and superfused with a warm (37 °C) Tyrode’s solution (described 
above). Drug treatment was performed with additive doses which were normalized to baseline. 
 
Adult cardiomyocytes 
CMs were isolated from New Zealand White male rabbits as previously described4. Animal 
experiments complied with the ARRIVE guideline for animal studies. The procedures used complied 
with current regulations and were approved by the Research Committee of the University of Glasgow. 
In total, 3 animals were used for these experiments. Sarcomere shortening was estimated using an 
ImageJ macro that calculates, for each image in a stack, the spatial frequency of the pixel intensity 
profile along a fixed, elongated rectangular region of interest placed inside the cell boundary and on a 
part of the cell showing clear banding. At each time point, mean sarcomere length corresponded to the 
location of the peak frequency value of the power spectrum obtained by taking the Fourier Transform 
of the intensity profile. Drug treatment was performed with single dose additions which were 
normalized to their pre-treatment baseline. 
 
Membrane labelling 
hPSC-CMs were plated on Matrigel-coated glass-bottom 24-well plates in either BPEL5 or 
Differentiation Medium C (Pluriomics b.v.) at a density between 20k-70k cells per well. Live cells 
were labelled with Cell Mask Deep Red (Thermo Fisher Scientific Inc.) and imaged with on a Nikon 
Ti-U Eclipse with a CamRecord CR600x2 monochromatic camera (Optronis GmbH) at 333 Hz after 
amplification of the image with an intensifier tube (Photonis b.v.). 
 
Engineered Heart Tissues 
EHTs were generated and analyzed as previously described6. In brief, hiPSC were differentiated into 
CMs with a growth factor based protocol in suspension culture using spinner flasks. 
Following dissociation with collagenase, fibrin-based EHTs were generated with 1x106 cells per 100 
µL EHT construct7. Contraction analysis based on a video-optical figure recognition algorithm (100 
frames per second) was performed under electrical stimulation in serum-free Tyrode’s solution in a 
humidified gas (40% O2, 7% CO2) and temperature (37 °C) controlled incubation chamber8. Drug 
treatment was performed with additive doses which were compared to baseline.	
Zebrafish hearts 
All experiments were conducted in accordance to the ARRIVE guidelines and approved by the local 
ethics committee of the Koninklijke Nederlandse Akademie van Wetenschappen (KNAW). Wild-
type, sibling and gnb5a/gnb5b double mutant embryos (5 days post fertilization) were embedded in 
0.3% agarose (Ultra Pure agarose, Invitrogen) prepared in E3 medium containing 16 mg/ml tricaine 
and mounted on glass bottom dishes. Recordings were performed at 28 °C using an inverted light 
microscope with climate chamber. Recordings were performed at 150 frames per second for 10-30 
seconds using a C9300-221 high-speed CCD camera (Hamamatsu Photonics K.K). Basal heart rates 
were recorded first. Subsequently 400 µM carbachol (CCh; Sigma-Aldrich) was added and incubated 
for 30 min before heart rates were measured a second time. 
 
Echocardiograms 
Anonymized ultrasounds of 5 adult patients who had undergone transthoracic echocardiography 
between 2012 and 2017 on clinical indication, were selected from the echocardiography database of 
the Leiden University Medical Center. Transthoracic echocardiography was performed using a GE 
Vivid7 or E9 (GE-Vingmed, Horten, Norway) ultrasound machine with standard views from the 
parasternal, subcostal, suprasternal and apical window. For MUSCLEMOTION analysis, 4 chamber 
views were used. The images were converted to avi-format, preferably containing multiple beats. For 
this analysis of clinically acquired data, the Institutional Review Board waived the need for patient 
written informed consent. 
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Online Figures  
 
 
 
 
 
Online Figure I 
Linearity of the contraction tool. 
a) Profiles of displacement (top) and velocity (bottom) when the block is moving along the x-axis;  
b) Profiles of displacement (top) and velocity (bottom) when the block is moving along the y-axis;  
c) Profiles of displacement (top) and velocity (bottom) when the block is moving along both axes. In 
all figures, the linearity between displacement and velocity is clearly preserved. 
 
 
 
 
  
 
 
 
Online Figure II 
Out-of-bounds limitation of the contraction tool. 
Demonstration of the out-of-bounds limitation occurring when the differences of moving areas in imgi 
an imgi-1 relative to imgref reached the maximum level. This is clearly visible in the clipping of the 
contraction plot. However, the velocity plot is still valid, since it calculates the difference between 
imgi and imgi-1. 
 
  
 
 
Online Figure III 
Automatic region of interest selection using maximum projection. 
First the difference from imgi to imgref is calculated. Next, the projection of the maximum intensity of 
the resulting image stack is generated. This projection is subjected to a threshold (standard set to the 
mean intensity of the projection image plus one standard deviation) and made binary. Next, this mask 
is used to analyze only the moving (contracting) areas.  
 
  
 
 
Online Figure IV 
Automatic reference frame detection. 
a) Example of  measured velocity profile.  
b) Velocityn values are plotted against velocityn+1 values. In order to select the point that has both low 
velocity and neighbour with similar values (two characteristics of a flat diastolic period, where the 
derivative is ideally zero) a number of points (in this example 50, blue) are selected that have the 
smallest distance to the origin.  
c) Magnification of a region in b). For each of the selected points, a number of points (in this example 
20, red) that are closet to the unity line (dotted red) is selected. Finally, of those points, one point 
(green) is selected as the smallest combination of values and distance from unity line. 
 
  
 
 
Online Figure V 
Examples of linearity checks for various cardiac models. 
The measured speed by frame-to-frame analysis (black) and calculated speed from the frame to 
reference frame analysis (red) of a) isolated adult rabbit cardiomyocyte contraction, b) fluorescent 
bead displacement by hPSC-CM on gelatin patterned polyacrylamide, c) engineered heart tissue 
contraction, d) contraction of fluorescently labelled monolayer, e) hPSC-CM monolayer contraction, 
f) hPSC-CM organoid contraction, g) single hPSC-CM contraction during patch clamp, h) zebrafish 
heart in vivo. 
 
 
  
 
Online Figure VI 
Results from EHT and Adult gold standards 
a) Representative average contraction profile obtained by pole deflection analysis of a single EHT 
during the recording period. b) Average dose-response curves (black traces) and single 
measurements for several parameters obtained in EHTs treated with isoprenaline (top, red) and 
nifedipine (bottom, green) by pole deflection analysis. c) Representative contraction profile obtained 
by sarcomere fractional shortening analysis of an adult rabbit CM. d) Average dose-response curves 
(black traces) and single measurements for sarcomere fractional shortening obtained in adult CMs 
treated with isoprenaline (top, red) and nifedipine (bottom, green). 
P-values baseline versus dose. Panel b i) 1 nM: 1; 3 nM: 1; 10 nM: 1; 30 nM: 1; 100 nM: 1. Panel b 
ii) 1 nM: 0.01517; 3 nM: 0.00016; 10 nM: 2.8·10-5; 30 nM: 8.8·10-7; 100 nM: 2.9·10-6. (N=6; 6; 6; 6; 
6; 6). Panel b iii) 3 nM: 1; 10 nM: 1; 30 nM: 1; 100 nM: 3.8·10-7. Panel b iv) 3 nM: 0.2095; 10 nM: 
0.0002; 30 nM: 5.2·10-10; 100 nM: 1.2·10-14. (N=6; 6; 6; 6; 6). Panel d i) 1 nM: 1; 3 nM: 0.018. Panel 
d ii) 10 nM: 1; 30 nM: 1; 100 nM: 0.00013; 300 nM: 0.00676. 
 
 Online Figure VII 
MUSCLEMOTION behaviour with different camera exposures. 
The output parameters of MUSCLEMOTION are shown for the same monolayer sample recordings 
with different exposure times. The contraction amplitude output increases linearly with increased 
exposure time while all temporal output parameters are independent of the lighting conditions within 
a reasonable range (i.e. the image should not be dark and it should not be saturated completely). 
 
  
 Online Figure VIII 
Negative controls of MUSCLEMOTION. 
The response of MUSCLEMOTION to a) a video of a single cell hPSC-CM that does not contract; b) 
a video of a contracting single cell hPSC-CM with baseline (i.e. diastolic period without contraction) 
indicated; c) a movie with extremely low exposure (i.e. black frames) and d) extremely high exposure 
(i.e. white frames). 
  
Online Movie Legends 
Online Movie I: test bench of block displacements. 
Online Movie II: single human stem cell derived cardiomyocyte during a patch clamp experiment. 
Online Movie III: human stem cell derived cardiomyocyte monolayer culture. 
Online Movie IV: human stem cell derived cardiac organoid. 
Online Movie V: Engineered heart tissue from human stem cell derived cardiomyocytes. 
Online Movie VI: isolated adult rabbit cardiomyocyte. 
Online Movie VII: Fluorescent bead displacement by a single hPSC-CM aligned on a gelatin 
patterned polyacrylamide substrate. 
Online Movie VIII: hPSC-CMs monolayer culture plated on a MultiElectrode Array. 
Online Movie IX: Fluorescently labelled hPSC-CMs monolayer. 
Online Movie X: Optical recording of a zebrafish heart (wildtype) in vivo. 
Online Movie XI: Human echocardiogram from healthy individual. 
Online Table I 
Overview of hPSC lines used in this study. 
 
Cell culture configuration hPSC cell line used 
Single cells with patch clamp LUMC0059iCTRL Clone 01 
Single cells aligned NIH CRM-5 (NCRM-5) 
Monolayers brightfield WT2a, Pluricytes® 
Monolayers membrane labelling NIH CRM-1 (NCRM-1) 
Monolayers on MEA WT2a and LQT1R594Qa 
Organoids NKX2-5(eGFP/w)b 
EHTs C25c and MYH7R453C isogenic triplet 
 
a Zhang et al., 2014. b from Elliott et al., 2011. c Mannhardt et al., 2016. 
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1 Before you begin
MUSCLEMOTION is a powerful and versatile ImageJ macro to measure in vitro or in
vivo muscle contraction or motion. Originally designed for quantifying 2D and 3D stem
cell derived cardiomyocytes contraction, it proved applicable to many diﬀerent cell types,
systems and experimental setups. Developed in a collaboration between the Leiden
University Medical Center and the University of Glasgow by a combination of biologists
and engineers, it aims to provide a simple software tool to quantify contraction without
the need for speciﬁc knowledge of software or expensive equipment. Furthermore, by
making MUSCLEMOTION open source, we encourage reproducible and open analysis
protocols and tools for open science.
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2 Algorithm explanation
This chapter describes the working of MUSCLEMOTION in detail. It can be used
to better understand and interpret the output data, select the correct parameters for
analysis or as a guide to developers that would like to improve the algorithm, in general
or for a speciﬁc purposes. Please refer to Sala L. et al., bioRχiv (2017), for further
information on the algorithm principle and applicability.
Basic principle
The principle underlying the algorithm is the assessment of contraction using an intuitive
approach to quantify absolute changes in pixel intensity between a reference frame and
the frame of interest, which can be described as
| imgi − imgref | = imgresult (1)
where imgi is the frame of interest, imgref is the reference frame and imgresult is the
resulting image. For every pixel in the frame, each reference pixel is subtracted from
the corresponding pixel of interest and the diﬀerence is presented in absolute numbers.
Unchanged pixels result in low (black) values, while pixels that are highly changed result
in high (white) values (see Figure 1). Next, the mean pixel intensity of the complete
resulting image is measured. This a quantitative measure of how much the pixel has
moved compared to the reference frame: more white pixels indicate more changing pixels
and, thus, more movement. When a series of images is analysed relative to the same
reference image, the output describes the accumulated change of displacement over time
(see Figure 1). However, if a series of images is analysed with a reference frame that
depends on the frame of interest (e.g. imgref = imgi−1), this results in a measure of the
relative diﬀerence between pixel intensities within a certain period of time, hence the
contraction velocity (see Figure 1).
Figure 1: Basic principle underlying MUSCLEMOTION.
An important parameter to understand is the speedWindow, which deﬁnes the num-
ber of frames that are used in the contraction velocity (imgref = imgi−speedWindow) and
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is set at 2 by default; other values can be used an depending on the noise, the frame rate
and the contraction duration of the sample that is being analysed. By increasing the
speedWindow, the noise in the speed of contraction can be reduced but by making the
speedWindow too large the output might become unreliable because of the high degree
of ﬁltering. Whether or not this is the case can be checked by inspection of the output
ﬁle Comparison calculated (red) and measured (black) speed.jpg (see Figure 10).
3 Requirements
Hardware
MUSCLEMOTION is an image processing tool and heavily relies on RAM usage. How-
ever, it is designed to work with ﬁle sizes larger than the RAM and is therefore not likely
to be limited by the amount of RAM, albeit computational time will be signiﬁcantly af-
fected. Similar considerations hold for the CPU. A high-speed recording camera, capable
of at least 60-75 frames per second, is required for the movie acquisition. A smartphone
camera with slow-motion feature (120/240 frames per second) is good as soon as it is
steadily mounted on the microscope. Several types of adaptors can be found online.
Software
MUSCLEMOTION runs on any operating system on which ImageJ is operational. MUS-
CLEMOTION has been developed and tested on ImageJ 1.51n, but is expected to work
with every ImageJ version. Please refer to the Installation section for more information
on how to download and install ImageJ. While MUSCLEMOTION is running, other use
of the computer should be avoided.
Input ﬁles
MUSCLEMOTION reads four types of ﬁles: uncompressed AVI, TIF stacks and PNG
or TIF image sequences (ordered alphabetically). Other video formats can be converted
with open source video conversion tool like FFmpeg. To ensure correct measurement
of the contraction the input ﬁles should obey to the Nyquist-Shannon criterium: the
recording speed (sample speed) should be at least twice as high as the fastest parameter
in the signal. In addition, the sampling speed should not be extreme, as frame to frame
diﬀerences could then become smaller than the noise. This can be corrected by choosing a
higher speedWindow (frame-to-frame distance, see Algorithm explanation and advanced
options).
4 Limitations
A small number of limitations should be taken in consideration before using MUSCLE-
MOTION. Since the algorithm is based on changes in pixel intensity, variations of the
lighting conditions during measurements should be avoided. Temporal parameters will
3
remain constant, but the contraction amplitude is changed linearly with an increase in
light, as shown in Figure 2.
Figure 2: Eﬀect of lighting conditions on output parameters.
If the periodicity of the contraction of interest is very symmetric (i.e. the duration
of the contraction is similar in length to the baseline) the correct reference frame might
not be detectable by the algorithm. It is therefore advised to check the output carefully,
especially at higher contraction frequencies. If a mistaken reference frame has been
selected, use the built-in manual reference frame selection tool (Figure 3).
Figure 3: Example of contraction proﬁle that might confound MUSCLEMOTION’s
automatic reference frame detection.
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5 Installation
Installation ImageJ
ImageJ or Fiji — which is ImageJ with many useful plugins included — (recommended)
can be downloaded from ImageJ NIH website or Fiji website, respectively. Download
and installation instructions can be found on the aforementioned websites.
Installing MUSCLEMOTION macro
The macro can be installed from ImageJ/Fiji by using the Plugins>Macros>Install
command and selecting the MUSCLEMOTION.ijm ﬁle. An icon with ”MM” will now
appear on the ImageJ/Fiji toolbar (see Figure 4).
Figure 4: ImageJ/Fiji toolbar button for MUSCLEMOTION.
Increase the memory for ImageJ/Fiji
Since most image calculations require quite a bit of RAM, it is advised to increase the
memory available for ImageJ/Fiji. To do so, select Edit>Options>Memory & Threads...
and increase the maximum memory. Please take into account the maximal available
RAM on the computer.
Figure 5: Memory increase.
Making a shortcut
To make sure ImageJ/Fiji shows the MUSCLEMOTION button after startup with-
out the need to install it every time, copy MUSCLEMOTION.ijm to [imageJ/Fiji in-
stallation folder]/macros and rename it to ”StartupMacros.ijm” (ImageJ) or ”Startup-
Macros.ﬁji.ijm” (Fiji). The button should now appear each time ImageJ/Fiji is started.
To run the macro simply click the MM button on the ImageJ/Fiji toolbar.
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6 Running MUSCLEMOTION
This simple demo ﬁle allows the user to check whether everything is working properly
and get to know the basic options of the algorithm. It is advised to run the demo before
loading other recordings.
The demo ﬁles can be found in the folder demo. A demo ﬁle called demo stack.tif
is included and a subfolder called demo results which contains the correct output ﬁles
which should be compared after running MUSCLEMOTION with the default settings.
Wizard
Once MUSCLEMOTION has been started, a wizard window will guide the user through
the customisation of the analysis settings. Default settings have been previously opti-
mised for stem cell derived cardiomyocytes. If selected, advanced options will be shown
in subsequent windows and will allow to customise parameters for multiple purposes.
A. Batch Analyses MUSCLEMOTION can perform analyses in batch throughout
multiple directories (max. 2 directories deeper than the starting directory). If ”Yes”
is selected, batch analyses will be performed on all the ﬁles contained in the chosen
directory (including subdirectories).
B. TIFF Images Sequence Some cameras only allows the recording of multiple
individual images instead of a combined movie/stack. Select ”Yes” if the recording
spans over multiple individual image ﬁles.
C. Gaussian Blur Some biological samples, as adult cardiomyocytes, have highly
repetitive structures that can profoundly inﬂuence the linearity of MUSCLEMOTION.
The application of a Gaussian blur cancels out the eﬀects of repetitive patterns on the
output precision. Select ”Yes” if you want to apply a Gaussian blur (σ = 10) to the
movie. The eﬀects of the added Gaussian blur will be visible in the image stack during
the analyses.
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D. Frame Rate Here you have to insert the frame rate at which the recordings have
been taken. This is important since the time scale of the output relies on this input
parameter. Please note that batch analyses must be performed on movies recorded with
identical frame rates.
E. Speed Window The Speed Window deﬁnes the frameshift in calculating the mea-
sure of contraction speed (”running diﬀerence”). The higher the value, the smoother
the curve, but it will also introduce a shift in time and amplitude. It is very useful with
high frame rate recordings. We recommend a Speed Window of 2-5 frames every 100 fps
to have a powerful but not intrusive ﬁlter in your outputs.
F. Noise Reduction Noise reduction is done by selecting the areas contributing most
to the contraction transient. By default, this setting is active from the beginning of the
recording to the end of the recording. If you prefer to avoid noise reduction, select ”No”.
If you prefer to customise the interval (in frames) over which the noise reduction will
take place, seek for the advanced options.
G. Automatic Reference Frame Detection MUSCLEMOTION can automatically
detect the reference frame, and this option is active by default. If you do not want an
7
automatic reference frame selection, press ”No” to manually pick the reference frame
in the movie with the built-in slider. The advanced options allow a customisation of
the reference frame selection interval and thresholds. Speciﬁcally, the number of low
points for automatic reference frame detection refers to the number of baseline values
(frames) among which a certain number of point close to the unity line will be identiﬁed
(respectively the blue and red dots in Figure S4 in the Paper).
Figure 6: Advanced options of the Reference Frame.
H. Transient Analysis MUSCLEMOTION allows the automatic quantiﬁcation of
contraction proﬁles. Advanced options include the possibility to modify both the tem-
poral and amplitude thresholds for the automatic identiﬁcation of contractile peaks.
Further options allows to select several contraction percentages as output as well as
the ﬁne-tuning of baseline and noise values. If the beating frequency of the sample is
high (diastolic phase ¡¡ systolic phase), please select ”Yes” in the last option; this will
automatically select the minimum baseline value before each peak.
Proceed with the analysis by FIRST selecting the directory in which the
8
Figure 7: Advanced options of the Transient Analysis.
results will be saved and, AFTER THIS, the directory/ﬁle that have to
be analysed.
7 Outputs
Once the analysis process has started, MUSCLEMOTION creates a directory in the
selected folder and ﬁlls it with all the output ﬁles. A Log window allows to track all the
steps in the analysis process and will be saved automatically at the end of the analysis.
(a) (b) (c)
Figure 8: Original movie, reference frame and binary contracting areas.
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Output Files
For each movie analysed, MUSCLEMOTION will generate 7 ﬁles, described in details
below.
Comparison calculated (red) and measured (black) speed.jpg: This image
overlays the calculated speed (red) and the measured speed (black) to have a rough
linearity check on the output. A good overlap between the two traces indicates that
MUSCLEMOTION worked within boundaries and, thus, the reliability of the results is
granted. In case these two traces were misaligned, please update the settings by adding
Gaussian blur or verify that the minimum requirements for frame rate and camera set-
tings are fulﬁlled.
Contraction.jpg: This graph contains a low-resolution representation of the contrac-
tion proﬁle. Vertical red lines indicate the temporal position of the identiﬁed contraction
peak, while horizontal/oblique lines graphically connect the percentages of the transient
previously chosen in the wizard procedure. Blue circles in diastole indicate the points
identiﬁed and used as baseline to quantify the contraction parameters. In case the high-
frequency transient detection option has been previously activated in the wizard, a blue
short segment marks the selected baseline value.
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Contraction.txt: This ﬁle contains the time course proﬁle of the contraction. This
values can be imported in other software for the generation of high-resolution graphs.
Log ﬁle.txt: This is the log ﬁle that contains a summary of the valuable information
useful to identify and reproduce the analysis. These include time stamps and duration,
a printout of the values of the used settings, the position in frames of the reference frame
and of the peaks.
Overview-results.txt: This ﬁle is structured as a table with headers and contains
the quantiﬁcation of the parameters extracted from contraction proﬁles.
Speed of contraction.jpg: This graph contains a low-resolution representation of the
speed of contraction proﬁle.
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Speed-of-contraction.txt: This ﬁle contains the time course proﬁle of the speed of
contraction. This values can be imported in other software for the generation of high-
resolution graphs.
8 Troubleshooting
Incorrect reference frame Sometimes MUSCLEMOTION fails to automatically de-
tect the reference frame. If this happens, please adjust the parameters for the automatic
selection in the advanced mode or manually select the reference frame.
9 How to cite
If you use MUSCLEMOTION in your publication, please cite it as: ”Sala L et al.,
Versatile open software to quantify cardiomyocyte and cardiac muscle contraction in
vitro and in vivo, bioRχiv, 2017, doi: 10.1101/160754”.
10 Contact
If you have a speciﬁc bug report for MUSCLEMOTION or would like to actively par-
ticipate in developing please email the authors:
Berend J van Meer, MSc
Luca Sala, PhD
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